Predicting Anti-TNF Response in IBD via Single-Cell RNA Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pediatric inflammatory bowel disease (IBD) lack precise biomarkers to predict response to anti-TNF-blockade therapy, leading to inefficiencies in treatment selection and progression of disease.
Innovation Solution
The method involves detecting specific T cell/Natural Killer/Innate lymphoid cell, myeloid, and epithelial cell subsets and gene expressions in patients at diagnosis to stratify them into risk groups (NOA, FR, PR) using single-cell RNA-sequencing, immunohistochemistry, or other techniques, allowing for tailored treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF-blockade therapy is administered to pediatric IBD patients, then disease control may be achieved in some patients, but treatment response cannot be predicted leading to ineffective treatment in non-responders
Solution Approach 1:
The patent performs single-cell RNA sequencing and biomarker detection at diagnosis before anti-TNF-blockade therapy is initiated. This preliminary action identifies patients who will respond to anti-TNF therapy versus those who will not, allowing clinicians to avoid ineffective treatment before it begins rather than determining response after treatment failure
Solution Approach 2:
The patent introduces cell subset frequencies (particularly T cells, Natural Killer cells, and Innate lymphoid cells) and gene expression profiles as intermediary biomarkers that mediate between the patient's baseline characteristics and treatment response. These biomarkers serve as predictive intermediaries that reveal which patients will respond to anti-TNF therapy without requiring trial-and-error treatment
2Productivity
If standard treatment protocols are used without biomarker stratification, then treatment simplicity is maintained, but treatment efficiency decreases due to inappropriate therapy selection
Solution Approach 1:
The patent segments the pediatric IBD patient population into distinct risk groups (NOA, FR, PR) based on single-cell RNA sequencing profiles and biomarker measurements. This segmentation divides patients into those who will not respond to anti-TNF therapy, full responders, and partial responders, allowing tailored treatment selection for each subgroup rather than uniform treatment protocols
Solution Approach 2:
The patent measures multiple parameters including frequencies of specific cell subsets (T cells, Natural Killer cells, Innate lymphoid cells), gene expression levels, and inflammatory markers to stratify patients. These parameter changes from baseline measurements enable prediction of treatment response and guide selection of appropriate therapy intensity
3Loss of time
If treatment is delayed or inappropriate for non-responders, then initial treatment costs are reduced, but disease progression occurs leading to worse outcomes
Solution Approach 1:
The patent performs predictive biomarker analysis at diagnosis before initiating anti-TNF therapy. This preliminary action identifies non-responders in advance, allowing clinicians to select alternative treatments immediately rather than delaying effective therapy until anti-TNF failure becomes apparent, thus preventing disease progression during the trial period
Data Source
AI summary
The subject matter disclosed herein is generally directed to stratifying and treating inflammatory diseases. In particular, the present invention provides for detecting treatment naive cell states that predict the response of a subject having inflammatory bowel disease to anti-TNF-blockade. The cells are T cells, NK cells, innate lymphoid cells, myeloid and/or epithelial cell subsets defined by their gene expression as determined by single cell RNA sequencing. Alternatively, the responders are identified by gene expression in a sample.